{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:05:27Z","timestamp":1790809527420,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00860-5","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T21:31:33Z","timestamp":1669411893000},"page":"77-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-2958","authenticated-orcid":false,"given":"Rohan","family":"Mital","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena","family":"Minta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Almhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jourdan","family":"Hydol-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Mallela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"issue":"5","key":"860_CR1","doi-asserted-by":"publisher","first-page":"E1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):E1690. https:\/\/doi.org\/10.3390\/ijms21051690.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"860_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"860_CR3","doi-asserted-by":"publisher","first-page":"13030\/qt8rw2j9z","DOI":"10.5070\/D3237035729","volume":"23","author":"Y Yao","year":"2017","unstructured":"Yao Y, Thomsen SF. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Dermatol Online J. 2017;23(7):13030\/qt8rw2j9zv.","journal-title":"Dermatol Online J"},{"key":"860_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jdcr.2020.12.036","volume":"9","author":"K Reardon","year":"2021","unstructured":"Reardon K, Levin J, Levin C. Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab. JAAD Case Rep. 2021;9:7\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.036.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"860_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13756","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Ruggiero A, Di Guida A, Patr\u00ec A, Fabbrocini G, Marasca C. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020;33(4): e13756. https:\/\/doi.org\/10.1111\/dth.13756.","journal-title":"Dermatol Ther"},{"issue":"4","key":"860_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.clindermatol.2021.05.026","volume":"39","author":"M Iannone","year":"2021","unstructured":"Iannone M, Janowska A, Tonini G, Davini G, Dini V. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during ixekizumab treatment for hidradenitis suppurativa. Clin Dermatol. 2021;39(4):701\u20132. https:\/\/doi.org\/10.1016\/j.clindermatol.2021.05.026.","journal-title":"Clin Dermatol"},{"issue":"6","key":"860_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.23736\/S0392-0488.18.06135-7","volume":"155","author":"G Odorici","year":"2020","unstructured":"Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa in a psoriatic patient. G Ital Dermatol Venereol Organo. 2020;155(6):788\u20139. https:\/\/doi.org\/10.23736\/S0392-0488.18.06135-7.","journal-title":"G Ital Dermatol Venereol Organo"},{"issue":"6","key":"860_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","volume":"71","author":"KB Gordon","year":"2014","unstructured":"Gordon KB, Leonardi CL, Lebwohl M, et\u00a0al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.048.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"860_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12852","volume":"32","author":"F Pirro","year":"2019","unstructured":"Pirro F, Caldarola G, De Simone C, Moretta G, Giovanardi G, Peris K. Multiple paradoxical reactions during ixekizumab therapy. Dermatol Ther. 2019;32(3): e12852. https:\/\/doi.org\/10.1111\/dth.12852.","journal-title":"Dermatol Ther"},{"issue":"6","key":"860_CR10","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, et\u00a0al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.005.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"860_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794","volume":"98","author":"A Schuch","year":"2018","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151\u20132. https:\/\/doi.org\/10.2340\/00015555-2794.","journal-title":"Acta Derm Venereol"},{"key":"860_CR12","doi-asserted-by":"crossref","unstructured":"Kimball AB, Alavi A, Jemec GBE. Secukinumab in moderate to severe hidradenitis suppurativa: primary endpoint analysis from the SUNSHINE and SUNRISE Phase 3 trials. 2022.","DOI":"10.25251\/skin.7.supp.129"},{"issue":"2","key":"860_CR13","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.15730","volume":"61","author":"G Babino","year":"2022","unstructured":"Babino G, D\u2019Ambra I, Fulgione E, Alfano R, Verolino P, Argenziano G. Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab. Int J Dermatol. 2022;61(2):e79\u201380. https:\/\/doi.org\/10.1111\/ijd.15730.","journal-title":"Int J Dermatol"},{"issue":"6","key":"860_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15116","volume":"34","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro RD, Pensa C, Lambiase S, Candi E, Bianchi L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol Ther. 2021;34(6): e15116. https:\/\/doi.org\/10.1111\/dth.15116.","journal-title":"Dermatol Ther"},{"key":"860_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdcr.2021.05.029","volume":"14","author":"A Flora","year":"2021","unstructured":"Flora A, Holland R, Smith A, Frew JW. Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab). JAAD Case Rep. 2021;14:33\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2021.05.029.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"860_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/bjd.19716","volume":"184","author":"E Marques","year":"2021","unstructured":"Marques E, Arenberger P, Smetanov\u00e1 A, Gkalpakiotis S, Zimov\u00e1 D, Arenbergerov\u00e1 M. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. Br J Dermatol. 2021;184(5):966\u20137. https:\/\/doi.org\/10.1111\/bjd.19716.","journal-title":"Br J Dermatol"},{"issue":"2","key":"860_CR17","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1111\/ajd.13559","volume":"62","author":"Y Kok","year":"2021","unstructured":"Kok Y, Nicolopoulos J, Dolianitis C. Tildrakizumab as a potential long-term therapeutic agent for severe hidradenitis suppurativa: a 15 months experience of an Australian institution. Australas J Dermatol. 2021;62(2):e313\u20136. https:\/\/doi.org\/10.1111\/ajd.13559.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"860_CR18","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1111\/ajd.13377","volume":"61","author":"Y Kok","year":"2020","unstructured":"Kok Y, Nicolopoulos J, Howard A, Varigos G, Kern J, Dolianitis C. Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa. Australas J Dermatol. 2020;61(4):e488\u201390. https:\/\/doi.org\/10.1111\/ajd.13377.","journal-title":"Australas J Dermatol"},{"key":"860_CR19","unstructured":"Janssen Research & Development, LLC. A Phase 2, multicenter, randomized, placebo-controlled, double-blind, proof-of-concept study to evaluate guselkumab for the treatment of subjects with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03628924. Accessed 29 Sep 2022."},{"issue":"1","key":"860_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","volume":"81","author":"RG Casseres","year":"2019","unstructured":"Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.017.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"860_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/ced.14199","volume":"45","author":"N Kearney","year":"2020","unstructured":"Kearney N, Byrne N, Kirby B, Hughes R. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. Clin Exp Dermatol. 2020;45(5):618\u20139. https:\/\/doi.org\/10.1111\/ced.14199.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"860_CR22","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/ccr3.3090","volume":"8","author":"AHR J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen AHR, Holm JG, Thomsen SF. Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn\u2019s disease: report and systematic literature review of effectiveness and safety. Clin Case Rep. 2020;8(12):2874\u20137. https:\/\/doi.org\/10.1002\/ccr3.3090.","journal-title":"Clin Case Rep"},{"key":"860_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15743","author":"M Agud-Dios","year":"2022","unstructured":"Agud-Dios M, Arroyo-Andr\u00e9s J, Rubio-Mu\u00f1iz C, Postigo-Lorente C. Successful treatment of hidradenitis suppurativa and Crohn\u2019s disease with combined guselkumab and apremilast. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15743 (Published online July 29).","journal-title":"Dermatol Ther"},{"issue":"7","key":"860_CR24","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1111\/jdv.18033","volume":"36","author":"DO Croitoru","year":"2022","unstructured":"Croitoru DO, Seigel K, Nathanielsz N, et\u00a0al. Treatment of severe hidradenitis suppurativa and fistulizing Crohn\u2019s disease with Guselkumab. J Eur Acad Dermatol Venereol JEADV. 2022;36(7):e563\u20135. https:\/\/doi.org\/10.1111\/jdv.18033.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"860_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14180","volume":"33","author":"C Garcia-Melendo","year":"2020","unstructured":"Garcia-Melendo C, Vilarrasa E, Cubir\u00f3 X, Bittencourt F, Puig L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol Ther. 2020;33(6): e14180. https:\/\/doi.org\/10.1111\/dth.14180.","journal-title":"Dermatol Ther"},{"issue":"7","key":"860_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15558","volume":"35","author":"FJ Melgosa Ramos","year":"2022","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Mateu Puchades A, Alfageme RF. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience. Dermatol Ther. 2022;35(7): e15558. https:\/\/doi.org\/10.1111\/dth.15558.","journal-title":"Dermatol Ther"},{"issue":"1","key":"860_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/09546634.2020.1755008","volume":"33","author":"T Montero-Vilchez","year":"2022","unstructured":"Montero-Vilchez T, Pozo-Rom\u00e1n T, S\u00e1nchez-Velicia L, Vega-Guti\u00e9rrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatol Treat. 2022;33(1):348\u201353. https:\/\/doi.org\/10.1080\/09546634.2020.1755008.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"860_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.21066","volume":"187","author":"SW Jiang","year":"2022","unstructured":"Jiang SW, Kwock JT, Liu B, et\u00a0al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022;187(3):417\u20139. https:\/\/doi.org\/10.1111\/bjd.21066.","journal-title":"Br J Dermatol"},{"issue":"3","key":"860_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.36849\/JDD.6298","volume":"21","author":"A Hollywood","year":"2022","unstructured":"Hollywood A, Murray G, Fleming S, Kirby B, Hughes R. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol JDD. 2022;21(3):319\u201320. https:\/\/doi.org\/10.36849\/JDD.6298.","journal-title":"J Drugs Dermatol JDD"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdin.2021.04.006","volume":"4","author":"RN Kaakati","year":"2021","unstructured":"Kaakati RN, Tanaka J, Liu B, et\u00a0al. Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: a single institution retrospective cohort study. JAAD Int. 2021;4:18\u201324. https:\/\/doi.org\/10.1016\/j.jdin.2021.04.006.","journal-title":"JAAD Int"},{"issue":"6","key":"860_CR31","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1111\/jdv.16280","volume":"34","author":"A Gambardella","year":"2020","unstructured":"Gambardella A, Calabrese G, Di Brizzi EV, Alfano R, Argenziano G. A case of atopic dermatitis and hidradenitis suppurativa successfully treated with dupilumab. J Eur Acad Dermatol Venereol JEADV. 2020;34(6):e284\u20136. https:\/\/doi.org\/10.1111\/jdv.16280.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"8","key":"860_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15645","volume":"35","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, Simonetti O, et\u00a0al. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa. Dermatol Ther. 2022;35(8): e15645. https:\/\/doi.org\/10.1111\/dth.15645.","journal-title":"Dermatol Ther"},{"issue":"1","key":"860_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, et\u00a0al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2015.3903.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"860_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","volume":"149","author":"K Zarchi","year":"2013","unstructured":"Zarchi K, Dufour DN, Jemec GBE. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149(10):1192\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5377.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"860_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/bjd.13292","volume":"172","author":"D Menis","year":"2015","unstructured":"Menis D, Maro\u00f1as-Jim\u00e9nez L, Delgado-Marquez AM, Postigo-Llorente C, Vanaclocha-Sebasti\u00e1n F. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172(3):810\u20131. https:\/\/doi.org\/10.1111\/bjd.13292.","journal-title":"Br J Dermatol"},{"issue":"6","key":"860_CR36","first-page":"772","volume":"15","author":"V Russo","year":"2016","unstructured":"Russo V, Alikhan A. Failure of anakinra in a case of severe hidradenitis suppurativa. J Drugs Dermatol JDD. 2016;15(6):772\u20134.","journal-title":"J Drugs Dermatol JDD"},{"issue":"11","key":"860_CR37","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1111\/ijd.14596","volume":"58","author":"R Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 R, Marescassier H, Gabay C, Pittet B, Laffitte E. Long-term therapy with anakinra in hidradenitis suppurativa in three patients. Int J Dermatol. 2019;58(11):e208\u20139. https:\/\/doi.org\/10.1111\/ijd.14596.","journal-title":"Int J Dermatol"},{"issue":"2","key":"860_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","volume":"70","author":"KS Leslie","year":"2014","unstructured":"Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.044.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"860_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaad.2021.07.032","volume":"87","author":"M Ravi","year":"2022","unstructured":"Ravi M, Trinidad J, Spaccarelli N, Kaffenberger B. The impact of comorbidity identification on outcomes in patients with pyoderma gangrenosum: a retrospective cohort study of previously hospitalized patients. J Am Acad Dermatol. 2022;87(1):194\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.032.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"860_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jaad.2018.02.007","volume":"79","author":"BH Kaffenberger","year":"2018","unstructured":"Kaffenberger BH, Hinton A, Krishna SG. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: a national survey. J Am Acad Dermatol. 2018;79(4):659-663.e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.007.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"860_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1389201021666200503050803","volume":"22","author":"E Molinelli","year":"2021","unstructured":"Molinelli E, Brisigotti V, Paolinelli M, Offidani A. Novel therapeutic approaches and targets for the treatment of neutrophilic dermatoses, management of patients with neutrophilic dermatoses and future directions in the era of biologic treatment. Curr Pharm Biotechnol. 2021;22(1):46\u201358. https:\/\/doi.org\/10.2174\/1389201021666200503050803.","journal-title":"Curr Pharm Biotechnol"},{"issue":"8","key":"860_CR42","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","volume":"98","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98(8):1821\u20136. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07581.x.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"860_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MGS, Shetty A, et\u00a0al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505\u20139. https:\/\/doi.org\/10.1136\/gut.2005.074815.","journal-title":"Gut"},{"issue":"4","key":"860_CR44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2018.10.006","volume":"80","author":"L Rousset","year":"2019","unstructured":"Rousset L, de Masson A, Begon E, et\u00a0al. Tumor necrosis factor-\u03b1 inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: a multicenter retrospective study. J Am Acad Dermatol. 2019;80(4):1141\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2018.10.006.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"860_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15716","volume":"35","author":"AS Kao","year":"2022","unstructured":"Kao AS, King AD, Daveluy S. Successful treatment of cabozantinib-induced pyoderma gangrenosum with ixekizumab therapy: a case report. Dermatol Ther. 2022;35(9): e15716. https:\/\/doi.org\/10.1111\/dth.15716.","journal-title":"Dermatol Ther"},{"issue":"11","key":"860_CR46","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.36849\/JDD.2020.1123","volume":"19","author":"MI Gul","year":"2020","unstructured":"Gul MI, Singam V, Hanson C, Neill BC, Aires DJ, Rajpara AN. Remission of refractory PASH syndrome using ixekizumab and doxycycline. J Drugs Dermatol JDD. 2020;19(11):1123. https:\/\/doi.org\/10.36849\/JDD.2020.1123.","journal-title":"J Drugs Dermatol JDD"},{"key":"860_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jdcr.2021.08.021","volume":"16","author":"IR Pollack","year":"2021","unstructured":"Pollack IR, Wolner ZJ, Hammett J, Swerlick RA. Pyoderma gangrenosum in a patient on ixekizumab. JAAD Case Rep. 2021;16:152\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2021.08.021.","journal-title":"JAAD Case Rep"},{"key":"860_CR48","doi-asserted-by":"publisher","first-page":"2050313X2094043","DOI":"10.1177\/2050313X20940430","volume":"8","author":"ML McPhie","year":"2020","unstructured":"McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20940430. https:\/\/doi.org\/10.1177\/2050313X20940430.","journal-title":"SAGE Open Med Case Rep."},{"issue":"9","key":"860_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15669","volume":"35","author":"J Coe","year":"2022","unstructured":"Coe J, Kudva S, Shams K. Matching the dose to the disease: successful treatment of recalcitrant pyoderma gangrenosum using high-dose secukinumab. Dermatol Ther. 2022;35(9): e15669. https:\/\/doi.org\/10.1111\/dth.15669.","journal-title":"Dermatol Ther"},{"issue":"7","key":"860_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15507","volume":"35","author":"M Li","year":"2022","unstructured":"Li M, Xiang H, Liang Y, et\u00a0al. Secukinumab for PASS syndrome: a new choice for therapeutic challenge? Dermatol Ther. 2022;35(7): e15507. https:\/\/doi.org\/10.1111\/dth.15507.","journal-title":"Dermatol Ther"},{"key":"860_CR51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.12688\/f1000research.52100.2","volume":"10","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, et\u00a0al. Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Research. 2021;10:381. https:\/\/doi.org\/10.12688\/f1000research.52100.2.","journal-title":"F1000Research."},{"issue":"2","key":"860_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.36849\/JDD.2020.4662","volume":"19","author":"A Toussi","year":"2020","unstructured":"Toussi A, Le ST, Barton VR, et\u00a0al. Successful management of anti-TNF-induced psoriasis despite continuation of therapy in a pyoderma gangrenosum patient. J Drugs Dermatol JDD. 2020;19(2):199\u2013201. https:\/\/doi.org\/10.36849\/JDD.2020.4662.","journal-title":"J Drugs Dermatol JDD"},{"issue":"6","key":"860_CR53","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.medcli.2018.06.011","volume":"152","author":"M Moreno Garc\u00eda","year":"2019","unstructured":"Moreno Garc\u00eda M, Madrid Gonz\u00e1lez M, Prada Lobato JM. Secukinumab for pyoderma gangrenosum: a case report. Med Clin (Barc). 2019;152(6):246. https:\/\/doi.org\/10.1016\/j.medcli.2018.06.011.","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"860_CR54","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1111\/1346-8138.14611","volume":"46","author":"K Jin","year":"2019","unstructured":"Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. 2019;46(3):e108\u20139. https:\/\/doi.org\/10.1111\/1346-8138.14611.","journal-title":"J Dermatol"},{"issue":"4","key":"860_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amjmed.2017.12.009","volume":"131","author":"J Pinard","year":"2018","unstructured":"Pinard J, Chiang DY, Mostaghimi A, Granter SR, Merola JF, Barkoudah E. Wounds that would not heal: pyoderma gangrenosum. Am J Med. 2018;131(4):377\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2017.12.009.","journal-title":"Am J Med"},{"issue":"1","key":"860_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13161","volume":"33","author":"U Wollina","year":"2020","unstructured":"Wollina U, Sch\u00f6nlebe J, F\u00fcrll C. Pyoderma gangrenosum induced by secukinumab\u2014a late paradoxical drug reaction. Dermatol Ther. 2020;33(1): e13161. https:\/\/doi.org\/10.1111\/dth.13161.","journal-title":"Dermatol Ther"},{"issue":"6","key":"860_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/01.ASW.0000744324.59877.df","volume":"34","author":"MA Weigelt","year":"2021","unstructured":"Weigelt MA, Kirsner RS. Peristomal pyoderma gangrenosum responding to risankizumab. Adv Skin Wound Care. 2021;34(6):327\u20139. https:\/\/doi.org\/10.1097\/01.ASW.0000744324.59877.df.","journal-title":"Adv Skin Wound Care"},{"issue":"4","key":"860_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/iwj.13359","volume":"17","author":"B Burgdorf","year":"2020","unstructured":"Burgdorf B, Schlott S, Ivanov IH, Dissemond J. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J. 2020;17(4):1086\u20138. https:\/\/doi.org\/10.1111\/iwj.13359.","journal-title":"Int Wound J"},{"issue":"7","key":"860_CR59","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ced.15183","volume":"47","author":"A Orita","year":"2022","unstructured":"Orita A, Hoshina D, Hirosaki K. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol. 2022;47(7):1372\u20134. https:\/\/doi.org\/10.1111\/ced.15183.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"860_CR60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/ajd.13196","volume":"61","author":"JM John","year":"2020","unstructured":"John JM, Sinclair RD. Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: killing two birds with one stone. Australas J Dermatol. 2020;61(2):170\u20131. https:\/\/doi.org\/10.1111\/ajd.13196.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"860_CR61","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1111\/ajd.13285","volume":"61","author":"Y Kok","year":"2020","unstructured":"Kok Y, Nicolopoulos J, Varigos G, Howard A, Dolianitis C. Tildrakizumab in the treatment of PASH syndrome: a potential novel therapeutic target. Australas J Dermatol. 2020;61(3):e373\u20134. https:\/\/doi.org\/10.1111\/ajd.13285.","journal-title":"Australas J Dermatol"},{"key":"860_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdcr.2021.11.030","volume":"21","author":"AM Reese","year":"2022","unstructured":"Reese AM, Erickson K, Reed KB, Ortega-Loayza AG. Modified dose of guselkumab for treatment of pyoderma gangrenosum. JAAD Case Rep. 2022;21:38\u201342. https:\/\/doi.org\/10.1016\/j.jdcr.2021.11.030.","journal-title":"JAAD Case Rep"},{"key":"860_CR63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jdcr.2020.12.005","volume":"8","author":"C Baier","year":"2021","unstructured":"Baier C, Barak O. Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2021;8:43\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.005.","journal-title":"JAAD Case Rep"},{"key":"860_CR64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2021.12.009","volume":"20","author":"J Nasseh","year":"2022","unstructured":"Nasseh J, Abi Rached H, Dumitru I, Staumont-Sall\u00e9 D, Dezoteux F. Pyoderma gangrenosum developing in a patient treated with dupilumab. JAAD Case Rep. 2022;20:58\u201360. https:\/\/doi.org\/10.1016\/j.jdcr.2021.12.009.","journal-title":"JAAD Case Rep"},{"key":"860_CR65","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Pollmann R, Schmidt T, et\u00a0al. Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol. 2019;10:1808. https:\/\/doi.org\/10.3389\/fimmu.2019.01808.","journal-title":"Front Immunol"},{"issue":"5","key":"860_CR66","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/jdv.17068","volume":"35","author":"C Rezzag-Mahcene","year":"2021","unstructured":"Rezzag-Mahcene C, Cardot-Leccia N, Lacour JP, Montaudi\u00e9 H, Passeron T. Successful treatment of recalcitrant genital lichen planus with secukinumab. J Eur Acad Dermatol Venereol JEADV. 2021;35(5):e321\u20133. https:\/\/doi.org\/10.1111\/jdv.17068.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"860_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bjd.16003","volume":"178","author":"R Maglie","year":"2018","unstructured":"Maglie R, Di Cesare A, Lazzeri L, et\u00a0al. Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment. Br J Dermatol. 2018;178(1):303\u20134. https:\/\/doi.org\/10.1111\/bjd.16003.","journal-title":"Br J Dermatol"},{"issue":"4","key":"860_CR68","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1111\/1346-8138.13637","volume":"44","author":"T Komori","year":"2017","unstructured":"Komori T, Honda T, Endo Y, Kaku Y, Otsuka A, Kabashima K. Oral lichen planus associated with candidiasis during secukinumab treatment. J Dermatol. 2017;44(4):e60\u20131. https:\/\/doi.org\/10.1111\/1346-8138.13637.","journal-title":"J Dermatol"},{"issue":"6","key":"860_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13967","volume":"33","author":"M Maurelli","year":"2020","unstructured":"Maurelli M, Colato C, Tessari G, Girolomoni G. Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab. Dermatol Ther. 2020;33(6): e13967. https:\/\/doi.org\/10.1111\/dth.13967.","journal-title":"Dermatol Ther"},{"issue":"2","key":"860_CR70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ajd.13793","volume":"63","author":"A Kherlopian","year":"2022","unstructured":"Kherlopian A, Fischer G. Successful treatment of vulvovaginal lichen planus with tildrakizumab: a case series of 24 patients. Australas J Dermatol. 2022;63(2):251\u20135. https:\/\/doi.org\/10.1111\/ajd.13793.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"860_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/ajd.13553","volume":"62","author":"A Kherlopian","year":"2021","unstructured":"Kherlopian A, Fischer G. Disease remission of refractory vulvovaginal and gingival lichen planus with tildrakizumab. Australas J Dermatol. 2021;62(2):246\u20137. https:\/\/doi.org\/10.1111\/ajd.13553.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"860_CR72","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1111\/ajd.13183","volume":"61","author":"FF Ismail","year":"2020","unstructured":"Ismail FF, Sinclair R. Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23\/interleukin-17 pathway in the pathogenesis of lichen planus. Australas J Dermatol. 2020;61(2):e244\u20135. https:\/\/doi.org\/10.1111\/ajd.13183.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"860_CR73","doi-asserted-by":"publisher","first-page":"e13694","DOI":"10.1111\/dth.13694","volume":"33","author":"L Trindade-de-Carvalho","year":"2020","unstructured":"Trindade-de-Carvalho L, Meah N, Wall D, Sinclair R. Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab. Dermatol Ther. 2020;33(4):e13694. https:\/\/doi.org\/10.1111\/dth.13694.","journal-title":"Dermatol Ther"},{"issue":"3","key":"860_CR74","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1111\/ajd.13263","volume":"61","author":"KL Kerkemeyer","year":"2020","unstructured":"Kerkemeyer KL, Pinczewski J, Sinclair R. Successful treatment of recalcitrant lichen planus pemphigoides with tildrakizumab. Australas J Dermatol. 2020;61(3):e366\u20138. https:\/\/doi.org\/10.1111\/ajd.13263.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"860_CR75","first-page":"415","volume":"100","author":"RR Knisley","year":"2017","unstructured":"Knisley RR, Petropolis AA, Mackey VT. Lichen planus pemphigoides treated with ustekinumab. Cutis. 2017;100(6):415\u20138.","journal-title":"Cutis"},{"issue":"11","key":"860_CR76","doi-asserted-by":"publisher","first-page":"13030\/qt30z7647","DOI":"10.5070\/D32111029305","volume":"21","author":"G Webster","year":"2015","unstructured":"Webster G. Failure of lichen planopilaris to respond to ustekinumab. Dermatol Online J. 2015;21(11):13030\/qt30z76472.","journal-title":"Dermatol Online J"},{"issue":"4","key":"860_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/1346-8138.15222","volume":"47","author":"D Niebel","year":"2020","unstructured":"Niebel D, Wilsmann-Theis D, Wenzel J. Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. J Dermatol. 2020;47(4):397\u2013401. https:\/\/doi.org\/10.1111\/1346-8138.15222.","journal-title":"J Dermatol"},{"issue":"2","key":"860_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00128071-200708020-00010","volume":"8","author":"N Yarom","year":"2007","unstructured":"Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol. 2007;8(2):121. https:\/\/doi.org\/10.2165\/00128071-200708020-00010.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"860_CR79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2340\/00015555-1249","volume":"92","author":"P Holl\u00f3","year":"2012","unstructured":"Holl\u00f3 P, Szakonyi J, Kiss D, Jokai H, Horv\u00e1th A, K\u00e1rp\u00e1ti S. Successful treatment of lichen planus with adalimumab. Acta Derm Venereol. 2012;92(4):385\u20136. https:\/\/doi.org\/10.2340\/00015555-1249.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"860_CR80","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/ddg.12224","volume":"12","author":"K Kreutzer","year":"2014","unstructured":"Kreutzer K, Effendy I. Therapy-resistant folliculitis decalvans and lichen planopilaris successfully treated with adalimumab. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2014;12(1):74\u20136. https:\/\/doi.org\/10.1111\/ddg.12224.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"issue":"4","key":"860_CR81","first-page":"246","volume":"18","author":"M Brennan","year":"2020","unstructured":"Brennan M, Baldissano M, King L, Gaspari AA. Successful use of rituximab and intravenous gamma globulin to treat checkpoint inhibitor- induced severe lichen planus pemphigoides. Skinmed. 2020;18(4):246\u20139.","journal-title":"Skinmed"},{"issue":"2","key":"860_CR82","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/bjd.13537","volume":"172","author":"K Heelan","year":"2015","unstructured":"Heelan K, McAleer MA, Roche L, McCreary C, Murphy M. Intractable erosive lichen planus treated successfully with rituximab. Br J Dermatol. 2015;172(2):538\u201340. https:\/\/doi.org\/10.1111\/bjd.13537.","journal-title":"Br J Dermatol"},{"issue":"4","key":"860_CR83","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/bjd.16704","volume":"179","author":"P T\u00e9tu","year":"2018","unstructured":"T\u00e9tu P, Monfort JB, Barbaud A, Franc\u00e8s C, Chasset F. Failure of rituximab in refractory erosive lichen planus. Br J Dermatol. 2018;179(4):980\u20131. https:\/\/doi.org\/10.1111\/bjd.16704.","journal-title":"Br J Dermatol"},{"issue":"4","key":"860_CR84","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.12788\/cutis.0232","volume":"107","author":"BT Pousti","year":"2021","unstructured":"Pousti BT, Jin A, Sklovar L, et\u00a0al. Dupilumab for the treatment of lichen planus. Cutis. 2021;107(4):E8\u201310. https:\/\/doi.org\/10.12788\/cutis.0232.","journal-title":"Cutis"},{"issue":"4","key":"860_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13542","volume":"33","author":"F Kemeriz","year":"2020","unstructured":"Kemeriz F, Acar EM, Ordu M. Omalizumab induced lichenoid drug eruption triggered by sun exposure. Dermatol Ther. 2020;33(4): e13542. https:\/\/doi.org\/10.1111\/dth.13542.","journal-title":"Dermatol Ther"},{"issue":"4","key":"860_CR86","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1081-1206(10)60343-2","volume":"102","author":"FO Seeborg","year":"2009","unstructured":"Seeborg FO, Rihal PS, Czelusta A, Sanchez R, Hanson IC. Lichen planus associated with omalizumab administration in an adult with allergic asthma. Ann Allergy Asthma Immunol. 2009;102(4):349\u201351. https:\/\/doi.org\/10.1016\/S1081-1206(10)60343-2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"860_CR87","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/ccr3.2871","volume":"8","author":"A Al-Janabi","year":"2020","unstructured":"Al-Janabi A, Marsland AM. Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: two case reports. Clin Case Rep. 2020;8(8):1458\u201360. https:\/\/doi.org\/10.1002\/ccr3.2871.","journal-title":"Clin Case Rep"},{"key":"860_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02362-y","author":"D Lukac","year":"2022","unstructured":"Lukac D, Pagani K, McGee JS. Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case-series study from a large, urban academic center. Arch Dermatol Res. 2022. https:\/\/doi.org\/10.1007\/s00403-022-02362-y (Published online June 18, 2022).","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00860-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T09:09:37Z","timestamp":1678784977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00860-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00860-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}